Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) Short Interest Update

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 74,200 shares, a decline of 20.0% from the May 30th total of 92,700 shares. Currently, 2.3% of the shares of the company are sold short. Based on an average daily volume of 346,100 shares, the short-interest ratio is currently 0.2 days.

An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new stake in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals as of its most recent SEC filing. 6.20% of the stock is owned by institutional investors and hedge funds.

DFFN remained flat at $$2.18 on Friday. 230,606 shares of the company’s stock were exchanged, compared to its average volume of 116,902. Diffusion Pharmaceuticals has a one year low of $1.83 and a one year high of $11.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.35 and a current ratio of 5.35. The stock has a 50-day simple moving average of $2.97. The stock has a market capitalization of $7.37 million, a P/E ratio of -0.36 and a beta of -0.02.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. On average, equities analysts forecast that Diffusion Pharmaceuticals will post -2.27 EPS for the current fiscal year.

DFFN has been the subject of a number of research reports. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. HC Wainwright restated a “buy” rating on shares of Advanced Emissions Solutions in a research report on Wednesday, March 20th.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.

Read More: What is a capital gain?

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.